Chimerix Stock Today
| CMRX Stock | USD 0.88 0.02 2.33% |
Performance0 of 100
| Odds Of DistressLess than 8
|
Chimerix is trading at 0.88 as of the 21st of November 2024; that is 2.33 percent increase since the beginning of the trading day. The stock's open price was 0.86. Chimerix has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Chimerix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of April 2013 | Category Healthcare | Classification Health Care |
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. Chimerix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 89.94 M outstanding shares of which 1.52 M shares are currently shorted by private and institutional investors with about 11.89 trading days to cover. More on Chimerix
Moving against Chimerix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Chimerix Stock Highlights
| President CEO | Michael MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsChimerix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Chimerix's financial leverage. It provides some insight into what part of Chimerix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chimerix (CMRX) is traded on NASDAQ Exchange in USA. It is located in 2505 Meridian Parkway, Durham, NC, United States, 27713 and employs 72 people. Chimerix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 79.14 M. Chimerix conducts business under Biotechnology sector and is part of Health Care industry. The entity has 89.94 M outstanding shares of which 1.52 M shares are currently shorted by private and institutional investors with about 11.89 trading days to cover.
Chimerix currently holds about 42.79 M in cash with (69.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49.
Check Chimerix Probability Of Bankruptcy
Ownership AllocationChimerix holds a total of 89.94 Million outstanding shares. 30% of Chimerix outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Chimerix Ownership Details
Chimerix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-06-30 | 695.6 K | |
| Acuitas Investments, Llc | 2024-06-30 | 638.7 K | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 600 K | |
| Northern Trust Corp | 2024-09-30 | 585.9 K | |
| Yakira Capital Management, Inc. | 2024-06-30 | 508.4 K | |
| Tejara Capital Ltd | 2024-06-30 | 414.4 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 388.5 K | |
| Assenagon Asset Management Sa | 2024-09-30 | 320.9 K | |
| State Street Corp | 2024-06-30 | 297.8 K | |
| Ra Capital Management, Llc | 2024-06-30 | 8.8 M | |
| Vanguard Group Inc | 2024-09-30 | 4.3 M |
Chimerix Historical Income Statement
Chimerix Stock Against Markets
Chimerix Corporate Management
| MD MBA | Chief Officer | Profile | |
| David CPA | Exec Officer | Profile | |
| Joshua Allen | Chief Imipridones | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Pablo MD | Head Affairs | Profile |
Additional Tools for Chimerix Stock Analysis
When running Chimerix's price analysis, check to measure Chimerix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimerix is operating at the current time. Most of Chimerix's value examination focuses on studying past and present price action to predict the probability of Chimerix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimerix's price. Additionally, you may evaluate how the addition of Chimerix to your portfolios can decrease your overall portfolio volatility.